UTI

Universal Technical Institute, Inc. to Participate in Upcoming May Investor Conferences

Retrieved on: 
Giovedì, Maggio 9, 2024
UTI, Universal Technical Institute, Fiscal

PHOENIX, May 9, 2024 /PRNewswire/ -- Universal Technical Institute, Inc. (NYSE: UTI) (the "Company"), a leading workforce solutions education provider, is scheduled to participate in the following investor conferences in May 2024:

Key Points: 
  • PHOENIX, May 9, 2024 /PRNewswire/ -- Universal Technical Institute, Inc. (NYSE: UTI) (the "Company"), a leading workforce solutions education provider, is scheduled to participate in the following investor conferences in May 2024:
    Location: Westin Grand Central Hotel in New York City, NY
    Presentation Date and Time: Wednesday, May 15th at 2:15 p.m. Eastern time
    Location: Beverly Hills Hilton in Beverly Hills, CA
    Fireside Chat Date and Time: Wednesday, May 22nd at 11:15 a.m. Eastern time
    For more information about the conferences or to schedule a meeting with management, please contact your respective conference representative or contact the Company's investor relations team at [email protected] .
  • Universal Technical Institute, Inc. recently announced its second quarter earnings for Fiscal 2024.
  • The company raised is fiscal year guidance for new student starts, revenue and profitability, and introduced its initial revenue and profitability projections for fiscal 2025.
  • For more details, see the press release here .

Universal Technical Institute Reports Fiscal Year 2024 Second Quarter Results

Retrieved on: 
Mercoledì, Maggio 8, 2024
UTI, Universal Technical Institute, Table, Nature, Social media, Teaching, Depreciation, School, Disease, Security (finance), Congress, Epidemic, Employment, Forecasting, Growth, Curriculum, Public expenditure, Disclosure, Regulation Fair Disclosure, COVID-19, Failure, Regulation, Bank statement, Student, Credit, GAAP, Veteran, Strategic planning, Bank

PHOENIX, May 8, 2024 /PRNewswire/ -- Universal Technical Institute, Inc. (NYSE: UTI), a leading workforce solutions provider of transportation, skilled trades and healthcare education programs, reported financial results for the fiscal 2024 second quarter ended March 31, 2024. Universal Technical Institute, Inc. operates in two reportable segments, Universal Technical Institute (UTI) and Concorde Career Colleges (Concorde), and together with its segments and subsidiaries is referred to as the "Company," "we," "us" or "our."

Key Points: 
  • Management will hold a conference call to discuss the financial results for the fiscal 2024 second quarter ended March 31, 2024, on Wednesday, May 8, 2024, at 4:30 p.m.
  • A live webcast of the call will be available via the Universal Technical Institute, Inc. investor relations website at https://investor.uti.edu .
  • Please go to the website at least 10 minutes early to register, download and install any necessary audio software.
  • Alternatively, the telephone replay can be accessed through May 22, 2024, by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and entering passcode 1518270.

TAR-210 results show 90% recurrence-free survival and 90% complete response in patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer, respectively

Retrieved on: 
Domenica, Maggio 5, 2024
UTI, Congress, FDA, FGFR, Cancer, Urinary diversion, Pyelonephritis, Erdafitinib, Hospital, Safety, Food, American Urological Association, Survival rate, FGFR3, Johnson & Johnson, Recurrence, Abstract, Cohort, BCG, PD-1, PD-L1, Disease, Bladder cancer, Patient, Medicine, AUA, Urinary bladder, MUC, Face, SAN, Sepsis, EAU, Pharmaceutical industry

SAN ANTONIO, May 5, 2024 /PRNewswire/ -- Johnson & Johnson announced today updated results from an open-label, multicenter, multi-cohort Phase 1 study of the safety and efficacy of TAR-210, an intravesical targeted releasing system designed to provide sustained, local release of erdafitinib into the bladder, in patients with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations. These data were featured today in an Oral Presentation Session (Abstract # PD48-02) at the 2024 American Urological Association (AUA) Annual Meeting taking place May 3-6, 2024, in San Antonio, Texas.

Key Points: 
  • First results were featured at the European Society for Medical Oncology 2023 Congress, with interim results presented at the European Association of Urology (EAU) 2024 Annual Congress.
  • "Results presented today further underscore that TAR-210 for the localized treatment of bladder cancer may offer a promising alternative for patients with limited treatment options."
  • At the data cutoff of March 22, 2024, 64 patients had been treated with TAR-210 across the 2 cohorts.
  • Of the 21 patients in C1 with HR-NMIBC, the 12-month recurrence-free (RF) survival rate was 90%.

Studies Show Continued Efficacy of New UTI Vaccine

Retrieved on: 
Sabato, Maggio 4, 2024
UTI, Vaccination, Interview, Woman, American Urological Association, Abstract (summary), Abstract, MD, Urology, Research, Urinary tract infection, Urogynecology, Communication, Infection, Annual general meeting, SAN, Female, Northwell Health

SAN ANTONIO, May 04, 2024 (GLOBE NEWSWIRE) -- Abstracts being presented at the American Urological Association's Annual Meeting discuss a new urinary tract infection (UTI) treatment as well as the UTI implications of weight management drugs.

Key Points: 
  • SAN ANTONIO, May 04, 2024 (GLOBE NEWSWIRE) -- Abstracts being presented at the American Urological Association's Annual Meeting discuss a new urinary tract infection (UTI) treatment as well as the UTI implications of weight management drugs.
  • Researchers will present their study findings covering important updates on UTI in San Antonio, Texas, from May 3 to 6.
  • “Fifty percent of women develop a urinary tract infection in their lifetime and a quarter will experience recurrent infections.
  • Treating this can be challenging for the patient and for providers,” said Dr. Lee.

Applied Digital Announces Appointment of Datacenter Industry Expert Todd Gale as Chief Development Officer

Retrieved on: 
Venerdì, Maggio 3, 2024
UTI, HPC, NAP, History, Engineering, GPU, Supercomputer, Growth, Management

DALLAS, May 03, 2024 (GLOBE NEWSWIRE) -- Applied Digital Corporation (Nasdaq: APLD) ("Applied Digital" or the "Company"), a designer, builder, and operator of next-generation digital infrastructure designed for High-Performance Computing (“HPC”) applications, today announced that Todd Gale has been appointed as Chief Development Officer, effective May 3, 2024.

Key Points: 
  • DALLAS, May 03, 2024 (GLOBE NEWSWIRE) -- Applied Digital Corporation (Nasdaq: APLD) ("Applied Digital" or the "Company"), a designer, builder, and operator of next-generation digital infrastructure designed for High-Performance Computing (“HPC”) applications, today announced that Todd Gale has been appointed as Chief Development Officer, effective May 3, 2024.
  • Mr. Gale brings over 45 years of expertise in collaborating with hyperscalers, driving transformative initiatives in datacenter design, engineering, construction, mission-critical infrastructure, mechanical and electrical engineering, and large-scale projects.
  • “We are happy to announce Todd Gale is joining our executive team as Chief Development Officer,” stated Wes Cummins, Chairman and CEO of Applied Digital.
  • With Todd’s distinguished history of fostering innovation and enhancing efficiency in datacenter development, we are set for extraordinary growth and achievements.”
    "Stepping into the role of Chief Development Officer at Applied Digital is a thrilling opportunity,” said Gale.

Keches Law Teams Up with Bosworth Law Filing Lawsuit Against Drug Manufacturer Bayer, Beth Israel Deaconess After UTI Antibiotic Leaves 44-Year-Old Walpole Woman Unable to Walk

Retrieved on: 
Giovedì, Maggio 2, 2024
UTI, Beth Israel, Blackbox, Talia, Superior, Docket, Lawsuit, Injury, Smith, Failure, Central nervous system, WFXT, Massachusetts General Hospital, Nursing

Smith alleges in the lawsuit that the Beth Israel Deaconess nurse practitioner who prescribed her Cipro for a minor UTI never explained any of the risks or side effects of Cipro.

Key Points: 
  • Smith alleges in the lawsuit that the Beth Israel Deaconess nurse practitioner who prescribed her Cipro for a minor UTI never explained any of the risks or side effects of Cipro.
  • As a result of her injuries, Smith has been hospitalized numerous times, even spending her 42nd birthday admitted to Massachusetts General Hospital.
  • Once a thriving employee climbing the ladder at her corporate job, Smith is now completely disabled and unable to work at all.
  • "No antibiotic that can permanently disable a healthy person should ever be prescribed in this country to treat a routine UTI," said Bosworth .

A link between breast changes and … UTIs?

Retrieved on: 
Giovedì, Maggio 2, 2024
UTI, CSHL, Urinary tract infection, TIMP1, Mouse, Risk, Pregnancy, Woman, Health, Cold Spring Harbor Laboratory, Research, Human, Metastasis, Cold, Infection, Menopause, Breast cancer, SPRING, Medical imaging

COLD SPRING HARBOR, N.Y., May 2, 2024 /PRNewswire/ -- Women's health is often talked about in terms of major, life-altering events like pregnancy and menopause. A new study from Cold Spring Harbor Laboratory (CSHL) underscores the importance of considering everyday occurrences' impact on women's well-being.

Key Points: 
  • The scientists found that UTIs in mice can provoke a bodily response that results in structural changes in breast tissue.
  • Cyrill notes that the breast changes that the team observed in mice with UTIs "were not directly caused by the infection itself.
  • Hormonal changes during pregnancy and menopause are known factors that can influence breast cancer risk .
  • They're now looking at how other changes women go through in their lifetimes might unexpectedly influence breast tissue.

Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis

Retrieved on: 
Giovedì, Aprile 11, 2024
Doctor of Philosophy, UTI, Mortality, Randomized controlled trial, Urinary tract infection, Safety, High Risk, Sepsis, Immunotherapy, Septic shock, Ventilation, Community-acquired pneumonia, System, Patient, Therapy, Overalls, Infection, Pharmaceutical industry

Enlivex intends to consider a potential follow-on, randomized, controlled study of a solely High Risk UTI sepsis population.

Key Points: 
  • Enlivex intends to consider a potential follow-on, randomized, controlled study of a solely High Risk UTI sepsis population.
  • The study was designed for patients to be randomized with equal degree of SOFA scores across treatment and placebo groups.
  • Both of these patient attributes are associated with a significantly higher degree of difficulty of treatment and higher mortality rates.
  • Nes-Ziona, Israel, April 11, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced positive indication of effect and safety results from its Phase II study of Allocetra™ in patients with sepsis, in which 120 patients enrolled.

Two Clinical Trials Identify a Better Way to Target Appropriate Antibiotics for Patients Hospitalized With Pneumonia or Urinary Tract Infection

Retrieved on: 
Venerdì, Aprile 19, 2024
Research, Infectious Diseases, Hospitals, Clinical Trials, Other Health, Health, Pharmaceutical, General Health, Science, Epidemiology, UTI, Infection, Physician, Harvard University, University, Urinary tract infection, JAMA, Pneumonia, Risk, Hospital, CDC, Bacteria, American Medical Association, Health care, INSPIRE, HCA Healthcare, Workflow, Patient, COVID-19, MPH, UCI, Fungus, Assistant, Harvard Pilgrim Health Care, Harvard Medical School, Journal, Division, Pharmaceutical industry

The two newly published studies, the INSPIRE Pneumonia and UTI Trials, involved more than 220,000 patients with pneumonia or UTI in 59 HCA Healthcare hospitals.

Key Points: 
  • The two newly published studies, the INSPIRE Pneumonia and UTI Trials, involved more than 220,000 patients with pneumonia or UTI in 59 HCA Healthcare hospitals.
  • This resulted in a better match for 28% of pneumonia patients and 17% of patients with UTI when compared to hospitals where physicians were not provided with alerts according to the trials.
  • The INSPIRE trials identified patients with low risk for antibiotic resistance and prompted physicians to order standard-spectrum antibiotics if extended-spectrum antibiotics were being ordered.
  • Additional information about the INSPIRE Pneumonia and UTI Trials can be found in the following JAMA author interview podcast.

FDA Approves New Treatment for Uncomplicated Urinary Tract Infections

Retrieved on: 
Mercoledì, Aprile 24, 2024
Urine, UTI, FDA, Public, Patient, Staphylococcus, Urinary tract infection, Pivmecillinam, Priority review, Safety, Woman, Cosmetics, Food, Dietary supplement, Heated tobacco product, Infection, Research, Human services, Bacteria, Nausea, Staphylococcus saprophyticus, Escherichia coli, Porphyria, Vaccine, History, Female, Therapy, System, Tablet, Diarrhea, Hypersensitivity, Multimedia, Animal, Proteus mirabilis, Clinical trial, Metabolic disorder, Division, Ibuprofen

SILVER SPRING, Md., April 24, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary tract infections (UTIs) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus.

Key Points: 
  • SILVER SPRING, Md., April 24, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary tract infections (UTIs) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus.
  • "The FDA is committed to fostering new antibiotic availability when they prove to be safe and effective, and Pivya will provide an additional treatment option for uncomplicated UTIs."
  • Uncomplicated UTIs are bacterial infections of the bladder in females with no structural abnormalities of their urinary tract.
  • Approximately one-half of all women experience at least one UTI in their lifetime.